Back to dashboard
Episode 34
DIP Episode 34 - Antivirals
Infectious DiseaseMedium4 - HighHas Q&A
Step 1Step 2Step 3COMLEXMedicineUSMLEStep 1Step 2Step 3
Topic
Herpesviruses (HSV, VZV, CMV); HIV life cycle and antiretrovirals; Hepatitis C/B treatment; Influenza antivirals.
Key Takeaway
Antiviral drugs target specific viral processes: acyclovir is a guanosine analog that acts as a chain terminator by requiring thymidine kinase for activation; ganciclovir targets the UL97 kinase and causes bone marrow suppression; HIV therapy uses fusion inhibitors (Enfuvirtide) or CCR5 blockers (Maraviroc); Hep C drugs target NS3/4A or NS5B proteins.
Runtime: 26.8 min
Published: 2018-06-01
Completed audio: Yes
Completed notes: Yes
Anki made: Yes
Section: MICROBIOLOGY, PHARMACOLOGY
Episode Notes
Source / episode info
- Episode: 34
- Title: Divine Intervention Episode 34 – Antivirals.
- Published: 2018-06-01
- Source: Episode page
One-liner
This episode provides a comprehensive review of antiviral agents, detailing mechanisms for herpesviruses (acyclovir, ganciclovir), HIV (fusion inhibitors, NRT Is/NNRT Is, integrase inhibitors), hepatitis viruses (NS3/4 A and NS5 B inhibition), and influenza (neuraminidase inhibition).
High-yield summary
- Herpes Treatment: Acyclovir is a guanosine analog that requires viral thymidine kinase for activation; its mechanism involves incorporating into DNA, where the lack of a 3'-hydroxyl group causes chain termination.
- CMV/HIV Therapy: Ganciclovir is the drug of choice for CMV and is activated by the UL97 kinase. Both ganciclovir and acyclovir can cause bone marrow suppression; if presented with bone marrow suppression due to an antiviral, consider ganciclovir first.
- HIV Entry Blockers: Maraviroc blocks the CCR5 receptor, preventing viral entry into T cells. Enfuvirtide is a fusion inhibitor that prevents the initial membrane fusion of HIV-1 (but not HIV-2).
- Hepatitis C/B: Hep C drugs target non-structural proteins: Bosirevir inhibits NS3/4 A, and Sofosbuvir inhibits NS5 B. Interferon-alpha is used for both Hep B and C but has significant side effects (e.g., depression history is a relative contraindication).
- Influenza: Neuraminidase inhibitors (Oseltamivir/Zanamivir) prevent the release of new viral particles by blocking the enzyme responsible for cleaving the sialic acid "feather." Treatment must be initiated within 48 hours and only reduces symptoms, not curing the infection.
Learning objectives
- Differentiate the mechanisms of action and clinical uses of acyclovir vs. ganciclovir in treating herpesviruses.
- Understand the role of CCR5 co-receptor blockade (Maraviroc) versus fusion inhibition (Enfuvirtide) in HIV management.
- Identify the specific viral proteins targeted by modern Hepatitis C drugs (NS3/4 A and NS5 B).
- Recognize that neuraminidase inhibitors are effective against both Influenza A and B, unlike older agents.
- Differentiate between interferon types: Alpha (Hep B/C), Beta (MS), and Gamma (CGD/Osteopetrosis).
Board exam buzzwords
| Condition | Key Finding | Association | Board Exam Tip |
| CMV | Mononucleosis-like syndrome, positive PCR | Acyclovir or Ganciclovir; UL97 kinase activation | If the patient has a mononucleosis picture but is negative for EBV/Mono, consider CMV and use ganciclovir. |
| HIV Infection | CCR5 mutation (e.g., Delta 32) | Maraviroc binding site | Blocking CCR5 with Maraviroc is highly specific; this mechanism is a key testable point. |
| Hepatitis C | NS3/4 A and NS5 B inhibition | Bosirevir, Sofosbuvir | Remember the two main targets: NS3/4 A (Bosirevir) and NS5 B (Sofosbuvir). |
| Influenza Virus | Neuraminidase enzyme activity | Oseltamivir/Zanamivir | These drugs prevent viral release by blocking the cleavage of sialic acid residues. Must be given within 48 hours. |
Rapid review table
| Topic | Key Point | Context | Exam Relevance |
| Acyclovir | Guanosine analog, chain terminator | Herpesviruses (HSV/VZV); activated by viral thymidine kinase | High selectivity; used for HSV and VZV. |
| Ganciclovir | Guanosine analog, chain terminator | CMV infection; activated by UL97 kinase | Drug of choice for CMV; monitor for bone marrow suppression. |
| Maraviroc | CCR5 receptor blocker | HIV-1 entry prevention | Specific mechanism that prevents the virus from binding to its co-receptor on T cells. |
| Oseltamivir | Neuraminidase inhibitor | Influenza A and B treatment | Effective against both subtypes; must be started within 48 hours of symptom onset. |
Board-speak -> diagnosis
| Board-speak / Vignette phrase | Diagnosis / Concept | Why it fits |
| A patient with CMV pneumonitis presents; treatment should involve a nucleoside analog that is activated by viral thymidine kinase. | Cytomegalovirus (CMV) Infection/Acyclovir | Acyclovir's mechanism relies on the virus-specific thymidine kinase for activation, making it highly selective and effective against CMV. |
| A patient with HIV infection presents; blocking the CCR5 receptor is a key therapeutic strategy. | Maraviroc Mechanism | Maraviroc specifically binds to and blocks the CCR5 co-receptor, preventing viral entry into T cells. |
| A combination therapy for chronic Hepatitis C involves an NS3/4 A inhibitor and an NS5 B inhibitor. | Hep C Treatment (e.g., Sofosbuvir/Velpatasvir) | This combination targets two critical non-structural proteins required for the replication cycle, representing current standard of care. |
| A patient with influenza presents 2 days after symptom onset; treatment should be initiated immediately to maximize benefit. | Neuraminidase Inhibitors (Oseltamivir) | These drugs must be given within 48 hours of symptom onset to reduce viral shedding and symptoms, though they do not cure the illness. |
| A patient with HIV is being treated; which drug class inhibits the protease enzyme? | Protease Inhibitors (e.g., Ritonavir) | Protease inhibitors prevent the cleavage of large polyproteins into functional individual proteins, halting maturation. |
| The most common side effect associated with high-dose antiviral therapy for chronic viral infections is metabolic syndrome. | Antiretroviral Therapy Side Effects | Many antiretrovirals (especially protease and integrase inhibitors) are known to cause dyslipidemia and insulin resistance, leading to metabolic syndrome. |
Differential diagnosis / distinguishing features
HIV Antiretrovirals (NRT Is vs NNRT Is)
| Key Features | Distinguishing Findings | Next Step |
| Nucleoside RT Is (NRT Is) | Competitive inhibitors; increase K_M, no change in V_{MAX}. Examples: Zidovudine, Tenofovir. | Use for combination therapy; monitor renal function (Tenofovir). |
| Non-Nucleoside RT Is (NNRT Is) | Non-competitive inhibitors; decrease V_{MAX}, no change in K_M. Examples: Nevirapine. | Used for combination therapy; watch for hepatotoxicity/hypersensitivity. |
Hepatitis Antivirals (Interferons)
| Key Features | Distinguishing Findings | Next Step |
| Interferon-alpha () | Treats Hep B and C; causes flu-like symptoms, depression risk. | Use for chronic viral hepatitis management. Screen for history of depression before use. |
| Interferon-beta () | Used specifically for Multiple Sclerosis (MS). | Treat MS relapses/progression. |
| Interferon-gamma () | Treats macrophage disorders; activates macrophages. | Use for Chronic Granulomatous Disease (CGD) or Osteopetrosis. |
Management pearls
- Always initiate antiviral therapy within 48 hours of symptom onset for influenza to maximize clinical benefit, even though it does not cure the illness.
- When treating CMV, use ganciclovir; if bone marrow suppression is noted on monitoring, consider alternative agents or dose adjustments.
- For HIV patients, combination antiretroviral therapy (cART) must include drugs from at least two different classes (e.g., NRT Is + Integrase Inhibitor).
- When administering protease inhibitors like Ritonavir, be aware of the risk for nephrolithiasis and monitor renal function closely.
Don't miss
🚨
Viral Specificity: Acyclovir is highly selective due to its requirement for viral thymidine kinase; this minimizes toxicity to host cells.
🚨
CMV Presentation: CMV can cause a mononucleosis-like syndrome, especially when the Monospot test is negative.
🚨
Hep C Targets: The two primary targets are NS3/4 A (inhibited by Bosirevir) and NS5 B (inhibited by Sofosbuvir).
🚨
Influenza Timing: Oseltamivir must be started within 48 hours; otherwise, the benefit is minimal.
Integration & clinical reasoning
- Pharmacology Integration: The concept of competitive vs. non-competitive enzyme inhibition is critical for understanding RT Is (NRT Is increase K_M; NNRT Is decrease V_{MAX}).
- Immunology Integration: Interferon-\gamma mimics T-helper 1 cell activity, activating macrophages and being used to treat macrophage deficiencies (e.g., CGD).
- Virology/Pharmacology Link: The use of nucleoside analogs (acyclovir, ganciclovir) demonstrates how drugs can be designed to exploit viral metabolic pathways for selective toxicity.
Concept connections / cross-references
- For a deeper dive into the mechanisms and clinical uses of various immune modulators, review [Episode 37].
- Understanding the full HIV life cycle is crucial; see the detailed virology discussion in [Episode 29].
High-yield association table
| Condition | Association | Mechanism | Clinical Significance |
| CMV | Mononucleosis-like syndrome | Viral replication/Cytokine release | Requires prompt diagnosis and treatment with ganciclovir. |
| HIV Infection | CCR5 receptor mutation | Blocks viral entry (Maraviroc) | Provides a therapeutic target for Maraviroc, making it highly specific to the co-receptor. |
| Hepatitis C | NS3/4 A and NS5 B inhibition | Direct protein inhibition | Modern combination therapy achieves high cure rates by targeting multiple non-structural proteins. |
| Influenza Virus | Neuraminidase enzyme | Cleavage of sialic acid residues (HA head) | Inhibitors prevent the release of new virions, limiting spread from infected cells to healthy ones. |
Key terms glossary
| Term | Definition | Context | Example |
| Chain Terminator | A molecule that incorporates into DNA/RNA but lacks a necessary functional group (like 3'-OH), halting polymerization. | Antivirals (Acyclovir, Ganciclovir) | Acyclovir prevents the formation of the phosphodiester bond at the 3' end of the growing chain. |
| CCR5 Receptor | Co-receptor on T cells used by HIV to gain entry into the host cell. | HIV Entry | Maraviroc blocks this receptor, preventing viral fusion with the cell membrane. |
| Neuraminidase Inhibitor | Drug class that prevents the cleavage of sialic acid residues from the influenza hemagglutinin (HA). | Influenza Treatment | Oseltamivir inhibits neuraminidase, trapping the virus on the infected cell surface. |
| Metabolic Syndrome | Cluster of conditions including dyslipidemia, hyperglycemia, and visceral adiposity. | Antiretroviral Therapy Side Effect | Protease inhibitors (e.g., Ritonavir) are notorious for causing this syndrome. |
Study optimization
| Topic | Study Approach | Priority | Resources |
| Antivirals | Mechanism of Action (MoA) comparison and drug class association. | High | Create flowcharts: Virus -> Target Protein/Enzyme -> Drug Class -> Specific Drug. |
| HIV Therapy | Understand the three main stages: Entry, Reverse Transcription, Integration. | Medium-High | Focus on which drugs block which step (e.g., Maraviroc blocks entry; NRT Is block RT). |
| Hepatitis Viruses | Memorize the specific non-structural proteins targeted by modern agents. | High | Use mnemonics: Hep C = NS3/4 A + NS5 B. |
Question pattern recognition
- Mechanism of Action (MoA) Questions: Identifying which drug class targets a specific viral enzyme or host receptor (e.g., CCR5, neuraminidase).
- Differential Diagnosis: Distinguishing between the causes and treatments for similar syndromes (e.g., CMV vs. EBV mononucleosis; Interferon types).
- Timing/Dosing Traps: Recognizing time-sensitive treatments (e.g., influenza within 48 hours) or specific contraindications (e.g., IFN-\alpha and depression history).
Test yourself
Common mistakes to avoid
🚫
Mistake 1: Confusing Antiviral Targets. Do not confuse the targets of acyclovir (thymidine kinase) and ganciclovir (UL97 kinase). Acyclovir is used for HSV/VZV, while Ganciclovir is preferred for CMV.
🚫
Mistake 2: Misunderstanding Influenza Inhibitors. Remember that neuraminidase inhibitors (Oseltamivir) work against both Influenza A and B, unlike older agents like amantadine.
🚫
Mistake 3: Antiviral Side Effects. Be aware of the class side effects; many antivirals can cause bone marrow suppression or metabolic syndrome.
Common traps
⚠️
Trap 1 (CMV/Mono): If a patient has mononucleosis symptoms but is negative for EBV, always consider CMV and initiate ganciclovir.
⚠️
Trap 2 (Influenza Timing): Never assume that because the drug works, it can be given days later; Oseltamivir must be started within 48 hours.
⚠️
Trap 3 (Interferon Confusion): Do not confuse IFN-\alpha (Hep B/C) with IFN-\beta (MS) or IFN-\gamma (CGD).
OMM / COMLEX integration
🦴
High-Yield Viscerosomatics, Autonomics & COMAT Shelf Clinical Pearls:
- Foregut Viscerosomatic Reflexes (T5–T9): Upper gastrointestinal structures (stomach, liver, gallbladder, spleen, and pancreas) receive sympathetic innervation from T5–T9 through the greater splanchnic nerve synapsing at the Celiac ganglion. Parasympathetic tone is supplied by the Vagus nerve (CN X). Palpate for acute tissue texture changes and right-sided paraspinal erythema at T5–T9 in acute cholecystitis or hepatitis.
- Chapman Reflex Points: Stomach (acidity) anterior point is located in the left 5th intercostal space mid-clavicular line; liver and gallbladder points are in the right 6th intercostal space. The pancreas anterior point lies in the right 7th intercostal space.
- Lymphatic Drainage & Mesenteric Lift: Celiac collateral ganglion inhibition (gentle posterior pressure over the epigastrium 1 inch below the xiphoid) down-regulates painful sympathetic spasm. In liver disease or portal hypertension, releasing the thoracic inlet and doming the abdominal diaphragm promotes venous return through the inferior vena cava and thoracic duct.